00:02 , Jun 26, 2019 |  BC Extra  |  Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
20:01 , Jun 20, 2019 |  BC Innovations  |  Translation in Brief

Turning Tregs against cancer

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
19:11 , Jun 11, 2019 |  BC Innovations  |  Distillery Therapeutics

CARD11, MALT1 inhibition sensitizes melanoma, colorectal tumors to PD-1 inhibitors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting CARD11 or MALT1 could help sensitize melanoma and colorectal cancer to PD-1 inhibitors. In mouse models of melanoma and colon cancer, conditional knockout of...
23:57 , Apr 18, 2019 |  BC Extra  |  Preclinical News

Pig brain tech could spur stroke therapies, drug and target validation

While Wednesday's announcement that Yale researchers restored cell function in postmortem pig brains sheds no light on the feasibility of reviving consciousness, it does suggest new opportunities for stroke treatments, disease models and validation of...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
23:27 , Mar 21, 2019 |  BC Extra  |  Clinical News

Conatus sinks after NASH therapy misses fibrosis endpoint

Conatus lost $1.49 (51%) to $1.42 in after-hours trading Thursday after reporting that emricasan missed the primary endpoint in the Phase IIb ENCORE-NF to treat non-alcoholic steatohepatitis fibrosis. ENCORE-NF's primary endpoint evaluated the proportion of...
18:01 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting CARD9 for colitis and Crohn's disease

DISEASE CATEGORY: Gastrointestinal; autoimmune disease INDICATION: Colitis; Crohn's disease Patient sample and mouse studies suggest inhibiting CARD9 could help treat colitis and Crohn's disease. In water lavage samples from Crohn's disease patients, the numbers of...
21:54 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Conatus' emricasan misses in Phase IIb for NASH cirrhosis

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week 24 vs. placebo in the Phase IIb ENCORE-PH trial...